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A holistic approach to dissecting 
SPARC family protein complexity 
reveals FSTL-1 as an inhibitor of 
pancreatic cancer cell growth
Katrina Viloria, Amanda Munasinghe, Sharan Asher, Roberto Bogyere, Lucy Jones & 
Natasha J. Hill
SPARC is a matricellular protein that is involved in both pancreatic cancer and diabetes. It belongs to a 
wider family of proteins that share structural and functional similarities. Relatively little is known about 
this extended family, but evidence of regulatory interactions suggests the importance of a holistic 
approach to their study. We show that Hevin, SPOCKs, and SMOCs are strongly expressed within islets, 
ducts, and blood vessels, suggesting important roles for these proteins in the normal pancreas, while 
FSTL-1 expression is localised to the stromal compartment reminiscent of SPARC. In direct contrast 
to SPARC, however, FSTL-1 expression is reduced in pancreatic cancer. Consistent with this, FSTL-1 
inhibited pancreatic cancer cell proliferation. The complexity of SPARC family proteins is further 
revealed by the detection of multiple cell-type specific isoforms that arise due to a combination of 
post-translational modification and alternative splicing. Identification of splice variants lacking a signal 
peptide suggests the existence of novel intracellular isoforms. This study underlines the importance 
of addressing the complexity of the SPARC family and provides a new framework to explain their 
controversial and contradictory effects. We also demonstrate for the first time that FSTL-1 suppresses 
pancreatic cancer cell growth.
The extracellular matrix (ECM) provides both structural support and regulates cellular responses. Diabetes 
results from an insufficiency of insulin-producing islet β cells and a failure of compensatory β cell growth and 
regeneration1. Worldwide, diabetes affects 415 million people and this figure is estimated to increase to 642 mil-
lion by 20402. The discovery of therapeutic mechanisms to stimulate β cell growth would allow physiological 
control of glucose levels and avoid many of the side effects and risks associated with poorly managed disease1. The 
pancreas is also the site of one of the most lethal types of cancer. Pancreatic ductal adenocarcinoma (PDAC) arises 
in the ductal epithelial cells of the pancreas and has one of the lowest 5-year survival rates of all cancers (< 5%). It 
also ranks as the seventh most common cause of death from cancer worldwide3. An underlying feature common 
to both diseases is the dysregulation of cell growth and survival, in which the extracellular matrix is likely to play 
an important regulatory role.
Pancreatic islets are surrounded by a basement membrane composed of ECM proteins such as collagens, 
laminin, and fibronectin4–6. Islets cultured in a collagen matrix showed improved β cell mass, survival and glu-
cose stimulated-insulin secretion compared to islets cultured in 2D7,8. The ECM and associated integrin signal-
ling have also been implicated in the pathogenesis of diabetes. For example, mice deficient in β 1 integrin have 
decreased β cell mass, proliferation, glucose tolerance and insulin production9,10.
In pancreatic cancer, the production of collagens I, III, and fibronectin is increased11–13 and matrix remodel-
ling enzymes such as MMPs and their inhibitors contribute to pancreatic cancer progression and metastasis14,15. 
Disruption of the basement membrane composition can lead to changes in apicobasal polarity and cause changes 
in cell shape and behavior. This has been shown to drive increased cell proliferation and tumourigenesis16–18. 
Stromal cells such as stellate cells, fibroblasts, endothelial cells and macrophages produce ECM proteins and 
also growth factors and cytokines that make up the extracellular environment. One of the hallmarks of PDAC 
is an extensive stroma that creates a protective capsule around the tumour and can constitute up to 80% of the 
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tumour mass19. Indeed, the tumour-stroma itself is now considered a therapeutic target in pancreatic cancer20,21. 
The regulation of cell growth and migration by the ECM and stromal cells underlies their important role in the 
progression of both pancreatic cancer and diabetes.
Central to the regulation of ECM structure and cell-matrix interactions are non-structural matricellular pro-
teins such as the SPARC family22. SPARC, or secreted protein acidic and rich in cysteine, is produced by stromal 
cells and regulates matrix remodelling and cell-matrix interactions23. SPARC has been shown to regulate cell 
adhesion and there is also evidence for a role in the regulation of cell growth and proliferation. SPARC modulates 
cell growth responses to a range of growth factors including TGF-β 24–30, binds to both β 1 integrins and collagen, 
and regulates collagen assembly and fibrillogenesis31–33. Hence SPARC determines cell responses to the ECM and 
controls multiple pathways fundamental to cell growth and adhesion.
SPARC is known to be highly expressed during development, wound healing and tissue regeneration 
and to play a role in angiogenesis, tumourigenesis and fibrosis23,34,35. In pancreatic cancer, stromal SPARC 
over-expression is strongly associated with poor patient prognosis36,37. Insulin resistance, diabetes and obesity 
are also associated with elevated levels of SPARC38–40. We have previously shown that SPARC is expressed by 
pancreatic stromal cells and is localised to the islet basement membrane. SPARC inhibits β cell and islet responses 
to growth factors28 and can also influence β cell function41. The production of SPARC by pancreatic stellate cells 
is regulated by metabolic parameters suggesting that SPARC may influence β cell loss and dysfunction in patients 
with type 2 diabetes28. SPARC is therefore involved in a number of pancreatic diseases, and SPARC expression 
and function in the pancreas is relatively well characterised. However, very little is known about the wider SPARC 
family of proteins, despite structural and functional similarities that suggest potentially similar roles.
The wider SPARC family consists of seven additional proteins: SPARC-like 1 or Hevin, SPOCK-1, -2, & -3, 
SMOC-1 and -2, and FSTL-1. As shown in Fig. 1, these proteins share three main domains: domain I – a highly 
acidic region with low affinity calcium binding; domain II- a follistatin-like domain consisting of kazal-like 
domains involved in growth factor binding; and domain III- a high affinity calcium binding domain with 2 
EF hands [also known as the EC domain] that is involved in collagen interactions. The EC and follistatin-like 
domains are well conserved within the family. In contrast, domain I is highly variable and, other than retaining 
an overall acidic nature, can be regarded as distinct in each SPARC family protein. In addition to these three 
Figure 1. Domain structure of the SPARC family of proteins. The SPARC family of proteins share three main 
domains: domain I- a highly acidic region with low affinity calcium binding, domain II- a follistatin-like domain 
containing kazal-like serine protease inhibitor domains, and domain III- a calcium binding EF hand domain 
(also referred to as the EC domain). The signal peptide (indicated by red boxes) is typically located in domain 
I except for SMOC proteins. Individual members of the SPARC family also have distinct domains: SPOCK 
proteins contain a thyroglobulin domain and a glycosaminoglycan binding domain, while SMOC proteins 
contain 2 thyroglobulin domains. FSTL-1 contains a von Willebrand factor type-C domain.
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domains, thyroglobulin domains are present in the SPOCK and SMOC proteins, a glycosaminoglycan-binding 
domain is present in the SPOCK proteins, and FSTL-1 contains a von Willebrand factor type-C domain.
Hevin is structurally the closest relative of SPARC and the two proteins have many overlapping roles. Like 
SPARC, Hevin can be anti-adhesive, modulates cell shape, binds to collagen and regulates collagen assembly42–45. 
While the role of Hevin in diabetes has not yet been examined, Hevin has been implicated in many cancers. 
Similar to SPARC, Hevin mRNA is overexpressed in pancreatic cancer compared to normal tissue. In fact, it has 
been suggested that proteolytic cleavage of Hevin creates a ‘SPARC-like fragment’ that can functionally compen-
sate for SPARC, and that as such Hevin acts as a SPARC reservoir46,47.
The SPOCK proteins also influence matrix characteristics, primarily through MMP regulation. For example, 
SPOCK-1 and SPOCK-3 inhibit membrane-type MMP (MT-MMP) activation of pro-MMP248, while SPOCK-2 
abrogates the inhibition of MT-MMPs by SPOCK-1 and SPOCK-349. MMPs are important regulators of cell 
migration and cell proliferation, for example through TGF-β activation50. The role of SPOCKs in diabetes is 
unknown but, as for SPARC, high expression of SPOCK-1 in the desmoplastic stroma of PDAC has been asso-
ciated with poor prognosis51. In other cancers, the increase in SPOCK-1 expression by TGF-β is thought to be 
involved in epithelial-mesenchymal transition (EMT)52, and tumour invasion of glioma cells was inhibited by 
SPOCK-3 transfection49. These studies suggest a role for SPOCK proteins in matrix remodelling and metastasis, 
and emphasize the importance of co-regulation between the SPOCK subfamily of proteins.
Although the role of SMOC proteins in the pancreas has not yet been examined, SMOC-1 is known to be an 
antagonist for TGF-β superfamily-BMP proteins53 and is important for stem cell differentiation54. SMOC-1 may 
also influence tissue remodelling by interaction with the matricellular protein tenascin-C55. In breast cancer, the 
SMOC-1 gene was found to be hypermethylated56 but otherwise very little is known about the role of SMOC-1 in 
human disease. There is similarly little known about the role of SMOC-2, although there is evidence that SMOC-2 
has mitogenic properties and is an important regulator of proliferation57, and can synergise with VEGF and 
bFGF-induced angiogenesis in endothelial cells58. Like SPARC, SMOC-2 may therefore regulate growth factor 
signalling. As for many matricellular proteins, SMOC-2 can also bind to integrins, and can promote cell attach-
ment and focal adhesion formation59.
FSTL-1 has the lowest homology to SPARC. It was first discovered as a TGF-β -induced protein and it has also 
been shown to bind directly to the TGF-β superfamily including BMPs60,61. In bone cancer cells, FSTL-1 was 
shown to promote metastasis62. On the other hand, the opposite was observed in ovarian and endometrial cancers 
where FSTL-1 was reported to be a tumour suppressor and increased the expression of apoptotic molecules such 
as caspases, and inhibited MMP2 expression and cell invasion63. As yet, the role of FSTL-1 in pancreatic cancer 
and diabetes is unknown. However, FSTL-1 is closely related to other follistatin-like proteins that have been 
implicated in pancreatic diseases. For example, FSTL-2, also known as IGFBP-7, is associated with insulin resist-
ance and type II diabetes64,65, and FSTL-2 down-regulation is associated with poor prognosis in PDAC patients66. 
Furthermore, FSTL-3 knockout mice have increased pancreatic islet number and improved insulin sensitivity67.
Hence, there is evidence that the extended SPARC family of proteins play similar roles to SPARC in regulating 
both the matrix and cellular responses to their environment. There is also growing evidence of coordinated reg-
ulation between SPARC family members, for example interactions between SPOCK proteins that regulate their 
function, and the potential overlapping function of Hevin and SPARC68. The presence of active proteolytic frag-
ments further adds to this complexity, and the SPARC family of proteins can also interact with other matricellular 
proteins. For example, SPARC interacts with TSP-169, and SMOC-1 with tenascin-C55. Ultimately, it will therefore 
be necessary to dissect the complexity and interactions of the SPARC family of matricellular proteins, and this 
may help resolve some of the contradictions and controversy regarding their function. The urgency is enhanced 
by the clinical importance of SPARC and other matricellular proteins as potential biomarkers and therapeutic 
targets70. To achieve this it will be necessary to take a systematic approach to understanding the function and 
complexity of the SPARC family of proteins. The aim of this study was therefore to investigate the expression of 
the extended SPARC family in the pancreas and provide a holistic analysis addressing their complexity in order 
to understand their role in pancreatic diseases.
Results and Discussion
Expression of the SPARC family of proteins in the pancreas. We have previously defined the expres-
sion of SPARC in the pancreas28, but the expression of other members of the SPARC family is currently not 
known. We therefore used immunohistochemistry to analyse the expression of all members of the wider SPARC 
family of proteins in pancreas sections, examining expression specifically in islets, ducts and blood vessels.
Hevin was detected throughout the islets, with stronger staining in selected cells primarily at the islet periph-
ery, as shown by the solid arrows in Fig. 2a panels (i) & (ii). In these cells, Hevin staining was observed primarily 
in the cytoplasm, although nuclear staining is apparent in some islet cells. Staining of the islet basement mem-
brane was also observed, as indicated by the dotted arrows in (i). Hevin was also expressed in blood vessels (iii), 
in connective tissues (iv), in ductal cells (v), and in selected cells in the acinar tissue (vi). Hevin expression in the 
normal mouse pancreas is therefore distinct to that observed in the human pancreas, where expression is much 
more restricted, and in islets appears localised specifically to stromal cells71, as we have observed previously for 
SPARC28.
As shown in Figs 2 and 3, the SPOCKs are also detected throughout islets, with strikingly strong expression 
of SPOCK-1 and SPOCK-3 in particular. The SPOCKs are also expressed in blood vessels, ductal cells and ductal 
basement membranes, and in selected acinar cells. SPOCK-1 staining was observed in the cytoplasm (Fig. 2b i–iii) 
but could also clearly be observed at the cell surface or extracellularly in ducts and in selected islet cells (arrows 
in Fig. 2b i and v), and was largely absent in the nucleus. A distinct perinuclear staining was observed in selected 
acinar cells (arrow in Fig. 2b vi). Similar to Hevin, SPOCK-2 also showed higher expression in cells at the islet 
periphery, and again staining was primarily evident in the cytoplasm as shown in Fig. 2c(i & ii). SPOCK-3 was 
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Figure 2. The SPARC family of proteins are widely expressed in the pancreas. ICR mouse pancreas sections 
were probed with antibodies to: Hevin (a), SPOCK-1 (b), and SPOCK-2 (c), followed by ABC-DAB staining 
(brown) and counterstained with haematoxylin (blue). Images are representative of 3–5 islets and ducts per 
section acquired using a 20X objective. Scale bar 100 μ m. n = 2–3 independent experiments from 3 different 
mouse pancreas. See main text for explanation of arrows.
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highly expressed in all islet cells and with primarily a cytoplasmic staining pattern (Fig. 3a i–iii), although a more 
restricted perinuclear staining was observed in scattered cells throughout the acinar tissue (Fig. 3a vi). The high 
Figure 3. The SPARC family of proteins are widely expressed in the pancreas. ICR mouse pancreas sections 
were probed with antibodies to: SPOCK-3 (a), SMOC-1 (b), SMOC-2 (c). See Figure legend 2 for additional 
details.
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levels of SPOCK expression in islets suggests that these proteins may play an important role in normal islet func-
tion, and it will be important for future studies to examine this further.
Both SMOC-1 (Fig. 3b) and SMOC-2 (Fig. 3c) were detected throughout the islet, with a range of staining 
intensity in different cells. For both proteins, the staining was again largely cytoplasmic, though strong nuclear 
SMOC-1 staining could also be observed in selected cells (eg arrow in Fig. 3b iii). The SMOCs were also expressed 
in blood vessels, in ductal cells (Fig. 3b and c panels iv, v & solid arrows in vi), as well as in the surrounding con-
nective tissue (dotted arrows in vi).
Within islets, FSTL-1 was expressed primarily in blood vessels and the islet basement membrane, although 
some weak diffuse staining can be observed throughout the islet (Fig. 4 i & ii). FSTL-1 was also expressed in large 
and small blood vessels throughout the endocrine and exocrine pancreas as well as in connective tissue (iii & iv). 
In ducts, FSTL-1 was clearly detected at the cell surface (vi), although some staining was also observed in the 
cytoplasm of ductal cells (v).
The SPARC family are defined as secreted matricellular proteins and contain signal peptide sequences to 
target them to the secretory pathway, as indicated in Fig. 1 (confirmed by Phobius database). They were therefore 
expected to be observed extracellularly. While Hevin, SPOCK-1 and FSTL-1 staining was observed at the cell 
surface, all members of the SPARC family also demonstrated cytoplasmic staining, and in some cases staining in 
the nucleus could also be observed. Cytoplasmic staining of SPARC family proteins has been previously described 
for Hevin72, SPOCK-173 and SMOC-259,74. It is likely that all SPARC family proteins are present in the extracellu-
lar environment, but this is not easily observed by immunohistochemistry when there is extensive cytoplasmic 
staining. However, the staining we observe clearly demonstrates the presence intracellularly of all SPARC family 
proteins. It will therefore be important to consider a possible intracellular role for these proteins in addition to 
their function in the extracellular matrix. One potential explanation for the intracellular location of these proteins 
is expression of splice variants lacking the signal peptide, and this is explored further below.
In summary, Hevin, the SPOCKs and the SMOCs were strongly expressed throughout islets consistent with 
expression in β cells. Furthermore, Hevin, SPOCK-2, and SMOC-2 showed stronger staining in cells at the 
islet periphery, consistent with higher expression in α cells. All SPARC family proteins were detected in ductal 
cells, while SPOCK-1, -2, -3, SMOC-1, and FSTL-1 were found also in ductal basement membranes. Hevin, the 
SPOCKs, the SMOCs and FSTL-1 were all found in selected acinar cells and in blood vessels throughout the pan-
creas. FSTL-1 on the other hand was not strongly expressed in islet parenchymal cells, but instead staining was 
consistent with expression primarily in islet basement membranes and blood vessels. This suggests that FSTL-1 is 
likely to be primarily expressed by stromal cells such as fibroblasts and endothelial cells, and the FSTL-1 staining 
pattern is highly reminiscent of SPARC expression28. The SPARC family of proteins are therefore clearly expressed 
in the pancreas, specifically in islet cells, stromal cells and pancreatic ducts, and warrant further investigation as 
to their function within the pancreas.
Identification of multiple isoforms of the SPARC family and their expression in specific pancre-
atic cell types. In order to confirm the expression of SPARC family proteins observed in pancreas sections, 
we analysed expression in specific cell types by western blot. Protein quantification was performed to ensure equal 
loading. Given that cell lysates were obtained from different cell types with variable actin expression it was not 
possible to standardise the samples to compensate for small variations in loading, and therefore only a qualitative 
analysis was performed.
Hevin was expressed in both INS-1 and MIN-6 β cells (Fig. 5a), in agreement with the islet staining pattern 
observed using immunohistochemistry, and was also expressed by stromal cells such as PS-1 stellate cells, MRC5 
fibroblasts and HUVEC endothelial cells, consistent with staining in basement membranes and blood vessels. 
Figure 4. The SPARC family of proteins are widely expressed in the pancreas. ICR mouse pancreas sections 
were probed with antibodies to FSTL-1. See Figure legend 2 for additional details.
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SPOCK-1, -2, and -3 were also clearly detectable in both β cell lines examined (Fig. 5b–d), consistent with stain-
ing in islet cells shown by immunohistochemistry, and were also expressed in stromal cells such as stellate cells, 
fibroblasts and endothelial cells. Although only weakly detected in MIN-6 cells, SMOC-1 was strongly expressed 
in INS-1 β cells (Fig. 5e), consistent with the IHC staining. SMOC-1 was also detected in endothelial cells, but is 
either absent or very weakly expressed in fibroblast and stellate cells. SMOC-2 on the other hand was not detected 
by western blotting (data not shown). FSTL-1 was not detected in β cells, consistent with the absence of staining 
in the majority of islet cells by immunohistochemistry. Instead, FSTL-1 was primarily detected in PS-1 stellate 
cells, with weak expression in fibroblasts and endothelial cells (Fig. 5f) consistent with basement membrane and 
blood vessel-like staining in pancreas sections.
A further striking observation in the series of western blotting experiments in Fig. 5 is the presence of multiple 
bands for all SPARC family proteins, with the exception of FSTL-1. We also observed clear evidence of cell-type 
specific expression of these isoforms. For example, amongst the cell types examined endothelial cells uniquely 
express a 65 kDa variant of SMOC-1. Similarly, only pancreas-derived cells expressed a 110 kDa isoform of Hevin, 
while β cells uniquely express high levels of an additional 39 kDa isoform. A summary of molecular weights 
detected for each protein is shown in Suppl. Table 1. As far as we are aware this is the first systematic analysis of 
multiple isoforms of the extended SPARC family of proteins. The identity of these isoforms and the mechanisms 
underlying the cell-type specific expression are not known. However, cell type specific expression of isoforms may 
well in part explain some of the contradictory and controversial effects of the SPARC family of proteins on cell 
function, and their often complex association with clinical diseases75.
Possible explanations for the observation of multiple isoforms include: (1) post-translational modifications 
such as phosphorylation, glycosylation and addition of glycosaminoglycans, (2) protein cleavage into peptide 
fragments46,47, (3) expression of alternative splice variants, (4) the use of alternative translational start sites76 and 
Figure 5. Identification of multiple isoforms of the SPARC family and their expression in specific cell 
types. For each of the indicated cell types 20–25 μ g of protein lysate was analysed by western blot using 
antibodies to Hevin (a), SPOCK-1 (b), SPOCK-2 (c), SPOCK-3 (d), SMOC-1 (e), FSTL-1 (f). Blots were 
cropped to show consistent bands observed in at least 2 independent experiments. Full, uncropped blots are 
shown in Suppl. Figure 2.
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(5) cross-linking by transglutaminase77,78. We therefore performed a systematic analysis of these factors for the 
wider SPARC family of proteins, combining both bioinformatics and experimental approaches.
Post-translational modification of the wider SPARC family of proteins. Potential glycosylation 
and phosphorylation sites for each extended family of SPARC protein were identified using GeneCards, UniProt, 
and Phosphosite Plus. As shown in Suppl. Table 2, Hevin can be extensively modified, with 12 potential glyco-
sylation sites and 8 phosphorylation sites. The SPOCKs also contain sites for both glycosylation and phospho-
rylation, and are known to contain O-linked glycosaminoglycans at serine residues in the C’ terminal region 
(Suppl. Table 2 and Figure 1). Glycosaminoglycan linkage can increase the molecular weight by 20 kDa or more79. 
SMOC-1 can be extensively modified through 9 glycosylation sites, compared to SMOC-2 with only 2 sites. Lastly, 
FSTL-1 has up to 3 sites for glycosylation and up to 5 for phosphorylation. All proteins in the extended SPARC 
family can therefore undergo varying degrees of post-translational modification.
Alternative splicing of the SPARC family of proteins. We previously performed an initial analysis of 
alternative splice variation in matricellular proteins80. To determine whether the protein isoforms observed in 
Fig. 5 could be due to alternative splicing we further analysed the SPARC family splice variants banked in the 
ENSEMBL database. As shown in Suppl. Table 3, there is evidence of a large number of splice variants for the 
SPARC family of proteins. In particular, 17 coding variants were identified for SPOCK-3. However, since some 
coding sequences (CDS) were found to be incomplete, we restricted our further analysis to coding variants for 
which the complete CDS is known. Protein FASTA sequences were obtained for complete CDS transcripts and 
domain structures were predicted using the InterPro database. As shown in Fig. 6, in many cases multiple splice 
variants encode highly similar proteins. However, for each of the extended SPARC family of proteins at least 
one alternative splice variant with distinct protein sequence was identified. In particular, for Hevin, SPOCK-1, 
SPOCK-3 and SMOC-2 at least one alternative variant lacking the signal peptide was identified, suggesting that 
both intracellular and extracellular isoforms of these proteins exist. The intracellular isoforms may explain the 
cytoplasmic staining for these proteins described in Fig. 1. It is also possible that intracellular isoforms exist 
for SPOCK-2, SMOC-1 and FSTL-1 for which the complete sequence is not yet known and was therefore not 
included in this analysis.
Figure 6. Predicted domain structures of alternative splice variants of the extended SPARC family. FASTA 
format protein sequences of the SPARC family alternative transcripts (complete CDS) were obtained from 
ENSEMBL and the InterPro database was used to determine domain structures. Numbers within domain 
structures indicate amino acid residues for each domain. Red boxes indicate the presence of a signal peptide. 
Alternative transcripts that do not contain the signal peptide are indicated with asterisks.
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Perhaps the most striking difference between isoforms of the extended SPARC family is the size of the acidic 
domain I, suggesting functional significance of domain I variation. However, the role of this domain is not well 
understood. Domain I is known to bind to calcium but with low affinity compared to the EC domain, and in 
SPARC domain I is involved in the regulation of cell migration81. In SPOCK-3, the acidic domain I is involved in 
MT-MMP inhibition48 while in SPOCK-2 it is involved in its regulation of SPOCK-349. This domain has diverged 
and acquired additional acidic residues during evolution82–85. It is also the least conserved domain between dif-
ferent SPARC family proteins, and is the primary feature that distinguishes SPARC from Hevin. Domain I may 
therefore confer diversity of function to each SPARC family protein, and this diversity is then further expanded by 
alternative splicing. This analysis therefore suggest the functional importance of domain I variation in the SPARC 
family of proteins.
Hevin isoforms – analysis of post-translational modification and splice variants. As described 
above, cell-specific expression of 110 kDa and 39 kDa Hevin isoforms was observed in addition to a widely 
expressed 49 kDa isoform. The predicted molecular weight of the Hevin precursor protein encoded by the pri-
mary transcript is 75 kDa, and the known Hevin splice variants for which the complete CDS is known are unlikely 
to explain the isoforms observed (Suppl. Table 3). However, 39–49 kDa Hevin bands have been reported to arise 
from cleavage by ADAMTS4 and MMP3, and Hevin is also a substrate for thrombin and plasmin digestion46,47. 
These low molecular weight Hevin proteins (39 and 49 kDa) are therefore likely to represent the products of enzy-
matic cleavage. The presence of the 39 kDa fragment exclusively in β cells suggests additional proteolytic cleavage 
of Hevin in these cells, perhaps reflecting a β cell specific role for Hevin fragments.
High molecular weight Hevin-reactive bands have also been previously observed44–46,86. Based on the num-
ber of predicted glycosylation sites (Suppl. Table 2), we hypothesized that the 110 kDa band is likely to reflect 
extensive glycosylation. To test this, we digested PS-1 stellate cell lysates with PNGase-F to test for the presence of 
N-linked glycosylation. As shown in Fig. 7a, an additional band at 36 kDa appeared following de-glycosylation. 
However, only the 49 kDa band and not the 110 kDa band showed any detectable decrease in intensity. The Hevin 
antibody used in these experiments recognises an epitope in the N-terminus and would therefore be predicted 
to recognise N-terminal cleavage products. These results therefore suggest that the 49 kDa band is a 36 kDa 
N-terminal cleavage product with approximately 15 kDa of N-linked glycosylation. The full length 110 kDa iso-
form may be conformationally resistant to glycosylase treatment or consist primarily of O-linked glycosylation. 
Alternatively, Hevin is predicted to be a substrate of transglutaminase (TRANSDAB)87, and the 110 kDa band 
may therefore represent oligomer formation due to cell-type specific cross-linking. Supporting this hypothesis, 
SPARC is also known to form oligomers as a result of transglutaminase-mediated cross-linking77,88.
Although no direct evidence of Hevin splice variants was observed in these experiments, subsequent experi-
ments using an alternative Hevin antibody recognising a C’ epitope revealed the presence of an additional third 
isoform in PS-1 cells at approximately 60 kDa (Suppl. Figure 1), whereas only two isoforms were detected in PS-1 
cells with the N’ antibody. This observation could suggest the presence of an alternative splice variant lacking the 
N-terminus. Consistent with this, Hevin variant 005 has a predicted molecular weight of 62 kDa (Suppl. Table 3). 
Since this variant lacks a portion of the N-terminal region it may exist in a conformation that is not recognised by 
the N-terminal antibody used. Variant 005 lacks a signal peptide and is predicted to be an intracellular isoform. 
However, mRNA studies would be required to confirm the detection of this potentially novel intracellular Hevin 
splice variant.
Proteolytic cleavage of Hevin has been shown to produce a “SPARC-like fragment”46,47 that is likely to corre-
spond to, or be contained within, the approximately 50 kDa band detected using the C-terminal Hevin antibody 
(Suppl. Figure 1). It has been suggested that this SPARC-like fragment may compensate for the loss of SPARC 
expression44,46,89. SPARC can be suppressed for example as a result of SPARC promoter methylation during 
tumourigenesis90. Furthermore, SPARC and Hevin have overlapping and compensatory roles in angiogenesis 
inhibition91. We therefore tested whether reducing SPARC expression in PS-1 stellate cells by siRNA knock-
down results in a compensatory increase in the presence of proteolytic cleavage products detected by both the 
N’- and C’-antibodies. As shown in Fig. 7b–e, despite achieving 90% knockdown of SPARC expression, no sig-
nificant change in the detection of either the full length Hevin or smaller fragments was observed with either the 
N-terminal or C-terminal antibodies.
Therefore, although previous reports have suggested that C-terminal Hevin fragments may compensate for 
loss of SPARC expression, we did not find evidence to support this hypothesis within the cell types examined. 
However, the various isoforms of Hevin that we have observed are likely to have distinct properties and to fulfill 
specific functions within the particular cell types where they are expressed, and there is evidence for the impor-
tance of additional proteolytic cleavage products specifically in β cells.
SPOCK protein isoforms. For each of the SPOCK proteins three different isoforms were observed. In the 
case of SPOCK-1, while an isoform of the predicted molecular weight (49 kDa) was observed in all cell lines 
examined, two additional isoforms (56 kDa and 100 kDa) were observed specifically in pancreatic stellate cells and 
β cells (Fig. 5b). SPOCK-1 has previously been detected in the 130–150 kDa range in human plasma and in kidney 
cells, and the increase in molecular weight is most likely due to the addition of large glycosaminoglycan chains 
(both chondroitin and heparin sulphate chains) at residues 383 and 388 of the C-terminus (Suppl. Table 2)79,92. 
The detection of SPOCK-1 at 49 kDa in all cell types suggests a native unglycosylated form of SPOCK-1 is also 
widely produced, and the addition of glycosaminoglycans in specific cell types may create novel functions. A 
33 kDa intracellular alternative splice variant was also identified in ENSEMBL (Suppl. Table 3 and Figure 6), and 
it is also possible that the observed 49 kDa and 56 kDa isoforms represent glycosylated forms of this variant.
Multiple splice variants of SPOCK-2 were also identified in ENSEMBL, primarily encoding variants highly 
similar to the primary transcript, with the exception of variant 202 that encodes a small (8 kDa) protein 
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Figure 7. Hevin contains N-linked glycosylated isoforms, but expression is not regulated by loss of SPARC 
expression. (a) PS-1 cell lysates were treated with PNGase-F glycosidase and analysed by western blot using 
antibodies to Hevin and β actin as a loading control. Images are representative of 3 independent replicates, 
and the mean molecular weight observed for each band is indicated next to the blots. Arrow indicates de-
glycosylated band. (b–e) PS-1 stellate cells were treated with anti-SPARC (+ ) or control (− ) siRNA for 48 hours. 
Cell lysates were then analysed by western blot using antibodies to SPARC to confirm knockdown (b), Hevin 
N-terminus (c), or Hevin C-terminus (d). On average 90% knockdown of SPARC expression was achieved in 
the three experiments performed (+ /− 6%). In (e), the graph shows mean signal intensity + /− SEM for the 
Hevin N-terminal antibody, standardised to β actin and relative to the control, for cells treated with SPARC 
(KD) or control siRNA. Images are representative of 3 independent replicates, and statistical significance was 
measured using the Student’s t-test (unpaired, two-tailed). p-values are indicated in the graph. Uncropped blots 
are shown in Suppl. Figure 4.
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containing a signal peptide but lacking any conserved domains (Fig. 6). However, proteins of such low molecular 
weight would not be observed by our western blot analysis. Proteins of around the expected molecular weight 
of the primary and similar transcripts (47 kDa) were observed in fibroblast and endothelial cells, though not 
in pancreatic stellate and β cells (Suppl. Table 1 and Figure 5c). In contrast, in β cells SPOCK-2 was detected at 
60 kDa and 120 kDa. As shown in Suppl. Table 2, SPOCK-2 contains both glycan and glycosaminoglycan binding 
sites, and variable glycosylation is therefore likely to explain the larger isoforms observed specifically in β cells. 
Interestingly, pancreatic stellate cells express very low levels of SPOCK-2.
For SPOCK-3 a large number of alternative transcripts were identified in ENSEMBL, with a total of 13 
protein-coding variants for which the complete coding sequence is known (Suppl. Table 3). Of these, multiple 
transcripts are predicted to produce a 49 kDa protein that is highly similar to the primary transcript in terms of 
predicted domain structure (001, 002, 006, 012, 014, 015, 016), as shown in Fig. 6. Interestingly, variants lack-
ing certain domains or with additional domains were also identified, encoding proteins of varying molecular 
weights between 36 and 44 kDa. For example, transcript 005 lacks the thyroglobulin domain and C’ glycos-
aminoglycan binding domain, while transcript 010 lacks the follistatin domain (Fig. 6). An alternative splice 
variant of SPOCK-3 missing the thyroglobulin domain and glycosaminoglycan binding sites has been previ-
ously described in kidney cells and glioma, referred to as N-Tes, that is likely to correspond to variant 005 in 
ENSEMBL48. SPOCK-3 transcript 013 contains a second thyroglobulin domain situated before the EC domain, 
almost pseudo-SMOC-like in structure. Interestingly, the thyroglobulin domain is involved in the IGF binding 
properties of IGFBPs, as well as protease inhibitory functions93–96, and it will therefore be interesting to test the 
function of splice variants either lacking (005) or with additional (013) thyroglobulin domains. SPOCK-3 splice 
variants also contain extensive variation within the acidic N-terminus, and this domain varies from just 12 amino 
acids in transcript 202, compared to 129 amino acids in the primary transcript. Importantly, transcripts 201, 017 
and 202 all lack the signal peptide and therefore are predicted to be intracellular proteins, consistent with the 
intracellular staining we observed in Fig. 3.
Since SPOCK-3 can also be glycosylated (Suppl. Table 2), the 65 kDa stromal isoform is likely to correspond to 
a glycosylated form of the 49 kDa protein encoded by the primary or similar transcripts. In order to test whether 
the variants we observe are due to glycosylation, we subjected PS-1 cell lysates to PNGase-F digestion. As shown 
in Fig. 8a, the 34 kDa isoform increases in intensity by at least four fold following digestion, suggesting that this 
isoform is present in both N-linked glycosylated and unglycosylated forms, and that the 34 kDa isoform is the 
unglycosylated form. Furthermore, a second band of 45 kDa also appears following digestion, suggesting the pres-
ence of a second distinct protein isoform that is normally N-glycosylated. The size of this band is consistent with 
the primary transcript, or an alternative transcript of similar size. These experiments demonstrate the presence 
of at least two isoforms of SPOCK-3 in stromal cells, most likely representing the primary 49 kDa transcript that 
exists in a glycosylated form and variant 005/N-Tes that can exist in both glycosylated and unglycosylated form 
(34–37 kDa). In contrast, only a single isoform is observed in β cells. The glycosylation detected by PNGase F treat-
ment may well represent N-linked glycosaminglycan chains attached to non-consensus N-glycosylation motifs. 
N-linked glycosylation at non-consensus motifs are now known to occur in mammalian genomes97. Multiple high 
molecular weight bands (> 90 kDa) were observed in PS-1 and β cell lysates at variable intensities, that are likely to 
reflect the addition of glycosaminoglycan chains (Suppl. Figure 2d). Mouse SPOCK-3 was recently shown to contain 
Figure 8. Expression of SPOCK-3 splice variants in pancreatic stellate cells. (a) PS-1 cell lysates were treated 
with PNGase-F glycosidase and analysed by western blot using antibodies to SPOCK-3 and β actin as a loading 
control. Images are representative of 3 independent replicates, and the mean molecular weight observed for 
each band is indicated next to the blots. Arrows indicate de-glycosylated bands. Uncropped blots are shown in 
Suppl. Figure 5. (b) PS-1 mRNA was isolated and expression of the indicated SPOCK-3 splice variant expression 
was analysed by RT-PCR.
www.nature.com/scientificreports/
1 2Scientific RepoRts | 6:37839 | DOI: 10.1038/srep37839
heparin sulphate proteoglycans, although N-linked glycosylation was not detected in mouse SPOCK-398. These 
experiments therefore demonstrate the novel finding that SPOCK-3 contains novel N-linked glycosylation sites.
As described above, the observation that two bands appear following de-glycosylation suggests the expression 
of two distinct core proteins, and is consistent with the presence of 005/N-Tes (~36 kDa) plus the full-length 
protein corresponding to the primary transcript or similar (~49 kDa) in PS-1 cells. However, other explanations 
are possible, including the presence of digestion products or differential post-translational modification in addi-
tion to N-linked glycosylation. We therefore sought to test whether distinct splice variant transcripts could be 
detected.
The exon structure of all 17 SPOCK-3 alternative splice variants banked in ENSEMBL was examined in order 
to design primers to detect variants. SPOCK-3 is unusual in that alternative splicing affects multiple regions 
across the entire coding sequence, as well as the 5′ UTR, suggesting that SPOCK-3 has a high degree of tolerance 
for variability within the protein structure80. Variants truncated at the 5′ end (201, 017, 202), at the 3′ end (005), 
and in internal regions (013, 010, 202, 018) are described in the database. As shown in Suppl. Figure 3, 19 exons 
are currently identified, the first 4 of which form the 5′ UTR. The 7 transcripts that encode proteins highly similar 
to the primary transcript are shown in blue. It can be seen that these variants differ primarily in the 5′ UTR exons, 
with 001/014, 002/015 and 006/16 pairs having identical coding sequences, differing only in the use of 5′ UTR 
exon 1/exon 2. In contrast, 012 uses 5′ UTR exon 4 which in fact contains an upstream translation start producing 
a predicted protein with an additional 12 amino acids at the N-terminus (translation performed using exPASY). 
However, it is not clear whether this start codon is used. Interestingly, exons 8 and 9 (as labelled in Suppl. Figure 3) 
are identical microexons of 9 bp. The coding sequences of 001, 014, 002 and 015 are therefore identical, and differ 
from 006/016 by only 3 amino acids. The significance of microexons is not fully understood, but they have been 
shown to have functional effects99,100, and have been previously identified in murine SPOCKs98. Since these 7 tran-
scripts produce highly similar proteins, we focused on transcripts predicted to encode medium length (201, 013) 
and short (017, 010, 202, 005) proteins for experimental confirmation.
Specific RT-PCR primers were designed to each of these variants, with the exception of transcript 017 for 
which unique primers could not be designed. The primer locations are shown in Suppl. Figure 3 and the sequences 
and predicted product sizes given in Suppl. Table 4. Generic primers were designed that should size differentiate 
between transcript 201 and the remaining transcripts (GenA), and that should amplify all transcripts listed except 
for 005 and 010 (GenB). As shown in Fig. 8b, we detected the 005 transcript in PS-1 cells, and the specificity of 
the PCR product was confirmed by Sangar sequencing. Transcripts 010, 201 and 202 were not detected using the 
primers specific to these sequences. The generic primers GenA and GenB detected PCR products of the expected 
size, and specificity was confirmed by Sangar sequencing. Since the GenB primers could not amplify 005 this con-
firms the presence of at least one other transcript in addition to 005, most likely the primary variant. The sequence 
of the GenA PCR product revealed the absence of microexons 8 and 9, and the sequence was instead identical to 
variants 006/016 (which have identical CDS). We therefore demonstrate that pancreatic stellate cells express two 
distinct SPOCK-3 splice variants, 005/N-Tes and 006/016, corresponding to the deglycosylated ~34 and ~45 kDa 
proteins observed by western blot.
Isoforms of the SMOC proteins. Two distinct isoforms of SMOC-1 were identified, with highly cell type 
specific expression (Fig. 5 and Suppl. Table 1). The 65 kDa isoform was expressed uniquely in endothelial cells, 
while the 53 kDa isoform was present primarily in β cells. Interestingly, SMOC-1 was either not detected or only 
weakly detected in fibroblasts and stellate cells. Only two splice variants with complete CDS were identified by 
bioinformatics analysis and both encode for highly similar 48 kDa proteins (Suppl. Table 3 and Figure 6), sug-
gesting that alternative splicing is unlikely to account for the two isoforms observed. However, SMOC-1 has 9 
predicted glycosylation sites (Suppl. Table 2) and therefore alternative glycosylation is more likely to explain the 
two distinct isoforms identified, as suggested by PNGase digestion in studies elsewhere54,101,102. It will therefore be 
important to analyse the effect of alternative glycosylation on SMOC-1 protein function to understand the roles 
of distinct isoforms in endothelial cells and β cells.
For SMOC-2, three alternative transcripts were identified in ENSEMBL: transcripts 001 and 002 are predicted 
to encode proteins of similar molecular weight (~50 kDa) and with overall similar domain structure, with the 
exception of a truncated acidic domain in 001 (Suppl. Table 3 and Figure 6). In contrast, variant 201 is predicted 
to encode a small 14 kDa protein that lacks a signal peptide and any predicted functional domains. The coding 
region of variant 201 is in fact not overlapping with that of the primary transcript and is therefore likely to encode 
an intracellular protein of quite distinct function. SMOC-2 has been previously detected between 54 kDa and 
60 kDa, and was shown to be glycosylated by PNGase digestion74,101.
SMOC proteins have been associated to many cancers and reported to be involved in cellular differentiation, 
cell-cycle progression and in regulating cell responses to the environment. However, SMOC proteins are largely 
unstudied in pancreatic diseases such as PDAC and diabetes. We have shown that SMOC-1 and SMOC-2 are 
widely expressed in the pancreas, and that specific SMOC-1 isoforms are expressed in endothelial cells and β cells. 
It will therefore be important to study the function of SMOC isoforms in these cells and in pancreatic disease.
Isoforms and expression of FSTL-1. Expression of FSTL-1 was the most highly specific of the SPARC 
family proteins. We detected strong expression of a single ~40 kDa isoform specifically in pancreatic stellate 
cells, with weaker expression in fibroblasts and endothelial cells (Fig. 5 and Suppl. Table 1). This is consistent 
with the stromal expression pattern and staining in basement membranes observed by immunohistochemistry 
(Fig. 4). We identified two alternative transcripts with complete CDS in ENSEMBL that are predicted to share 
the same functional domains except for a truncated acidic domain in variant 004 (Suppl. Table 3 and Figure 6). 
Both variants contain a signal peptide sequence and are therefore predicted to be secreted extracellular pro-
teins. The molecular weight of the observed protein (40 kDa) is consistent with the predicted molecular weight of 
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the primary transcript with minor post-translational modification such as glycosylation, as has been previously 
reported103. FSTL-1 is sometimes overlooked as a member of the SPARC family since it has the least structural 
and sequence homology to SPARC and it has been suggested that the calcium binding EF hand in FSTL-1 may be 
non-functional103. Our data shows that FSTL-1 is expressed by stromal cells within the pancreas with an expres-
sion pattern highly reminiscent of SPARC28, and is expressed at high levels specifically by pancreatic stellate cells. 
This suggests that FSTL-1 may play a related role to SPARC in pancreatic disease and that the function of FSTL-1 
warrants further study.
Despite SPARC-like expression pattern, exogenous FSTL-1 does not regulate β cell growth 
or proliferation. Compared to other SPARC family proteins that we have shown to be highly expressed 
throughout islets and in β cells, FSTL-1 and SPARC are the only SPARC family proteins detected in stromal cells 
and not in β cells by western blotting and IHC (Figs 4 and 5 and ref. 28). Like SPARC, FSTL-1 has been shown to 
regulate signalling of the TGF-β superfamily and to regulate growth factor signalling28,39,60,61,104,105. We therefore 
tested whether FSTL-1 can similarly regulate β cell growth. INS-1 β cells were treated with rFSTL-1 over a period 
of 3 days. Cell growth was measured using the Incucyte Zoom live cell imaging system, and cell proliferation 
was measured by BrdU incorporation over the final 24 hour period. However, as shown in Fig. 9, the addition of 
exogenous FSTL-1 had no effect on the growth or proliferation rate of β cells. Despite a highly similar pattern of 
expression to SPARC, FSTL-1 is therefore unlikely to be directly involved in the regulation of islet growth and 
survival.
FSTL-1 inhibits cancer cell proliferation. Although we did not observe any change in the growth or 
proliferation of β cells in response to FSTL-1, previous reports have suggested that FSTL-1 can act as a tumour 
suppressor in breast and ovarian cancer63. We therefore examined the effect of FSTL-1 on pancreatic cancer cell 
growth and proliferation. The addition of rFSTL-1 was found to inhibit the growth (Fig. 10a & b) and proliferation 
(Fig. 10c) of pancreatic cancer cells. Western blotting revealed that FSTL-1 is only expressed by pancreatic stro-
mal cells and not by cancer cells (Fig. 10d). However, both stellate cells and cancer cells express DIP2A (Fig. 10e), 
which acts as a receptor for FSTL-1106,107. Analysis of FSTL-1 immunohistochemistry data in the Human Cancer 
Atlas database shows that FSTL-1 is expressed at ‘medium’ levels in the normal pancreas but is not detected in the 
majority of pancreatic cancer tissues analysed108. Furthermore, FSTL-1 is similarly reduced compared to normal 
tissue in a range of other cancers including liver, breast, renal and stomach cancer108. Together, this data suggests 
that FSTL-1 produced by stromal cells normally acts to inhibit pancreatic cancer cell growth, and that FSTL-1 
expression is downregulated within pancreatic tumours. Whether this difference is clinically significant would 
require further analysis that is outside the scope of this study. However, the data suggests that FSTL-1 is a novel 
tumour suppressor in pancreatic cancer. Furthermore, SPARC and FSTL-1 produced by stromal cells have oppos-
ing effects on pancreatic cancer cell growth, and it will therefore be of interest in future studies to test whether the 
combined signature of SPARC overexpression and FSTL-1 inhibition is useful diagnostically.
Conclusions
The SPARC family of matricellular proteins are important multifunctional regulators of cellular and matrix inter-
actions. Our data shows that the extended SPARC family is expressed in pancreatic β cells, stromal cells and in 
ducts. We identified multiple isoforms with cell-type specific expression that arise from a complex mixture of 
post-translational modifications and expression of alternative splice variants. Furthermore, intracellular vari-
ants of the wider SPARC family were also identified, and these are likely to have distinct functions compared 
to secreted variants. We have further shown that FSTL-1 inhibits pancreatic cancer cell growth, suggesting that 
SPARC and FSTL-1 produced by stromal cells have antagonistic effects on cancer cell growth.
We have shown that taking a systematic and holistic approach to the study of the SPARC family of proteins 
and addressing the complexity of the different isoforms will be essential for understanding the function of these 
proteins and their role in health and disease, and is likely to represent an important challenge for the field. This 
study therefore provides a foundation for future research investigating the SPARC family in pancreatic diseases 
such as diabetes and cancer.
Methods
Animals. Pancreas sections for immunohistochemistry were obtained from adult male and female outbred 
ICR mice (21–25 g) from Harlan, Bicester, UK. Tissues were fixed in 10% NBF and embedded in paraffin. Animal 
maintenance was performed in accordance with the principles of laboratory animal care. No procedures covered 
by UK Home Office Regulations were carried out in this study.
Immunohistochemistry. Paraffin embedded sections (5 μ m) of ICR pancreas were deparaffinised in histo-
clear (National Diagnostics) or histochoice (Amresco) and hydrated with 100% and 70% ethanol. Blocking was 
performed using 10% normal horse serum for 30 minutes in a humidified chamber. Antibodies to the SPARC 
family of proteins were selected to ensure that the epitope was either within the unique acidic domain I, or 
outside of any highly conserved domains. Full details of the antibodies used and concentrations are given in 
Suppl. Table 5. Primary antibodies were incubated overnight, followed by incubation with relevant biotinylated 
secondary antibody for 1 hour at room temperature. Antibody binding was detected using ABC peroxidase kit 
with DAB substrate (Vector Labs). Sections were counterstained with haematoxylin. Adjacent sections were 
stained in parallel with the relevant secondary antibody only as a negative control, and this was blank in all exper-
iments. Digital images were acquired using a Nikon Eclipse 80i microscope and analysed using ImageJ software.
Cell Culture. PS-1 pancreatic stellate cells and MRC5 fibroblast cells were kindly provided by Professor 
Hemant Kocher from the Barts Cancer Institute, Queen Mary University of London. AsPC-1, Hpaf, Capan-1, 
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Panc-1 pancreatic cancer cells and INS-1 β cells were kindly provided by Dr. Charlotte Edling from the Blizzard 
Institute, Barts and the London. MIN-6 β cells were kindly provided by Professor Peter Jones of King’s College 
London. HUVEC endothelial cells were kindly provided by Dr. Andrew Snabaitis at Kingston University, London.
Figure 9. FSTL-1 does not regulate β cell growth and proliferation. INS-1 β -cells were plated at a density 
of 1.5 × 104 cells/well in a 96 well plate. Post synchronisation, the cells were either provided with untreated 
medium or medium supplemented with 100 ng/ml rFSTL-1 in either 10% FBS (a,b) or 0.5% FBS (c,d) 
and cultured for a further 72 hrs. Cell growth was monitored every 12 hrs during this period using the 
IncuCyteZOOM live cell imaging system. In (a,c) graphs shows mean cell confluence relative to control + /− 
SEM, n = 30 from 5 independent experiments, while representative images taken at the indicated timepoints are 
shown in (b,d). BrdU incorporation was measured for the last 24 hrs of the 72 hr culture, and the graph in (e) 
shows mean absorbance relative to the control + /− SEM. Statistical significance was measured using Student’s 
t-test (unpaired, two-tailed) and p-values are indicated in the graph.
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PS-1, AsPC-1, Hpaf, Capan-1, and Panc-1 cells were grown in RPMI-1640 media supplemented with 2 mM 
L-glutamine, 100 μ g/ml penicillin and streptomycin, and 10% FBS (Gibco). INS-1 β cells were grown in RPMI-
1640 supplemented with 2 mM L-glutamine, 100 μ g/ml penicillin and streptomycin, 1 mM sodium pyruvate, 
10 mM HEPES buffer, 0.05 mM β -mercaptoethanol and 10% FBS. MIN-6 β cells and MRC5 fibroblasts were grown 
in DMEM media supplemented with 100 μ g/ml penicillin and streptomycin and 10% FBS. HUVEC cells were 
Figure 10. FSTL-1 inhibits pancreatic cancer cell growth and proliferation. AsPC-1 cancer cells were plated at a 
density of 5 × 103 cells/well in a 96 well plate. Post synchronisation, the cells were cultured in complete media (10% 
FBS) containing the indicated concentrations of rFSTL-1 for 72 hrs. Cell growth was monitored every 12 hrs during 
this period using the IncuCyteZoom live cell imaging system. (a) Graph shows mean cell confluence relative to the 
control + /− SEM, n = 17–18 data pooled from 3 independent experiments, and representative images taken at 
72 hrs are shown in (b). BrdU incorporation was measured for the last 24 hrs and the graph in (c) shows the mean 
absorbance relative to the control + /− SEM n = 16–17 data pooled from 3 independent experiments. Statistical 
significance was measured using one-way ANOVA and p-values are indicated in the graph (*p < 0.05, ◊p < 0.01 
, †p < 0.001, ‡p < 0.0001). (d) FSTL-1 expression in pancreatic cancer cells was analysed by western blotting. 
Uncropped blots are shown in Suppl. Figure 6. (e) RT-PCR was performed on the indicated cell lines using primers 
specific for DIP2A, or QARS as a housekeeping gene. A single PCR product of the expected size was observed for 
both primer pairs, and all negative controls were blank.
www.nature.com/scientificreports/
1 6Scientific RepoRts | 6:37839 | DOI: 10.1038/srep37839
grown in F12K media supplemented with 100 μ g/ml penicillin and streptomycin, 0.1 mg/ml heparin, 50 μ g/ml 
ECGS (Millipore), and 10% FBS. Cells were incubated at 37 °C in 5% CO2.
Cell growth assays. INS-1 β -cells (1.5 × 104 cells/well) and AsPC-1 (5 × 103 cells/well) pancreatic cancer 
cells were plated in a 96 well plate and synchronised in low serum media (0.5% FBS) for 24 hrs. Post synchronisa-
tion, the cells were either provided with fresh untreated medium or with medium containing various concentra-
tions of rFSTL-1 (R&D Systems) and cultured for further 72 hrs. Cell growth was monitored every 12 hrs during 
this period using the IncuCyteZOOM live cell imaging system (Essen Bioscience). BrdU incorporation (Roche 
Applied Science) was measured for the last 24 hrs of the 72 hr culture according to the manufacturer’s instruc-
tions. Statistical significance was calculated using Student’s t-test (unpaired, two-tailed) or one-way ANOVA and 
a p-value <  0.05 was considered significant.
siRNA knockdown. Transfection complexes were formed using human SPARC siRNA (J-003710-10 
Dharmacon) and HiPerFect (Qiagen) in serum-free medium for 20 minutes at room temperature. Human 
non-targeting siRNA was used as a control (Dharmacon). During this period PS-1 cells were plated at a density 
of 1 × 105 cells per well in a 24 well plate. Transfection reagents were then added to the cells to give a final concen-
tration of 80 nM siRNA. Transfection was carried out for 48 hours and knockdown was confirmed by western blot 
with SPARC antibody. Hevin isoforms were then detected using antibodies specific to the N- and the C-terminus 
(see Suppl. Table 5 for antibody details).
Protein expression analysis by Western Blot. Cells were lysed with RIPA buffer (Sigma Aldrich) for 
20 minutes on ice in the presence of protease inhibitors (HaltTM Protease Inhibitor Single Use Cocktail). Lysates 
were subsequently cleared by centrifugation and the supernatant collected. Samples were run immediately after 
lysis to avoid potential issues with protein degradation86. For glycosylase experiments, cell lysates were denatured 
at 100 °C for 4 minutes then incubated with PNGase-F for one hour at 37 °C according to the manufacturer’s 
instructions (New England BioScience).
Protein concentration was determined using the BCA protein assay (Bio-Rad DC). Sample buffer was added 
to lysates after which equal protein was loaded onto 12% polyacrylamide gels and subjected to SDS-PAGE 
(20–25 μ g of protein/well). Proteins were then transferred onto nitrocellulose membranes and blocked with 5% 
milk solution. Membranes were incubated overnight at 4 °C with the relevant rabbit SPARC family primary anti-
body (see Suppl. Table 5) and mouse β -actin antibody (1:2500, Abcam) then washed with Tween TBS. Anti-rabbit 
and anti-mouse secondary antibodies conjugated respectively to IR800 and IR700 infra-red dyes were used for 
detection. Membranes were visualised by infrared using a Li-Cor Odyssey CLx scanner. Molecular weight and 
signal intensity was measured using Li-Cor Image Studio. Image processing of greyscale images for figure prepa-
ration was limited to changes in brightness and contrast applied to the entire blot, and in some cases the image 
was flipped to invert the order, or the order of the wells changed for clarity and consistency. In all cases the images 
shown are an accurate representation of the original data. Cropped blots are used in the main paper and the full 
uncropped blots are shown in supplementary data. Statistical significance was calculated using Student’s t-test 
(unpaired, two-tailed) and a p-value < 0.05 was considered significant.
mRNA expression analysis by RT-PCR. Total RNA was isolated from PS-1 cells using an RNeasy Mini 
Kit, including on-column DNase I treatment (Qiagen). Total RNA was quantified using a NanoVue™ Plus 
Spectrophotometer and RNA integrity confirmed using an Agilent Bioanalyzer 2100. RNA (700 ng) was reverse 
transcribed to cDNA using a RevertAid First Strand cDNA Synthesis Kit (ThermoFisher Scientific). PS-1 cDNA was 
amplified using DreamTaq Green PCR Master Mix (ThermoFisher Scientific). Primers were designed to SPOCK-3 
splice variants banked in ENSEMBL (Accessed March 2013) using PrimerBLAST (See Suppl. Table 4 and Suppl. 
Figure 3). Primer sequences used for DIP2A were: Forward primer- GCAGATGGTGTCCCTGTGAAC Reverse 
primer- CTGATTTGGATCTGGTTGCTGA. At least one primer in each pair was designed to be exon spanning to 
avoid amplification of any residual genomic template. RT-PCR products were separated on a 2% agarose gel in TAE. 
QARS primers (for-TTCCGGTGTCTCTGCAATGG; rev- CTGCTGAGCCTGAGTAGCG) were used as a load-
ing/positive control. All negative controls were blank (no RT cDNA, no template cDNA, and PCR dH20 control).
Bioinformatics. The ENSEMBL database was used to identify alternative splice variants of the human SPARC 
family of proteins. Only protein-coding transcripts for which the complete coding sequence (CDS) is known were 
included in the analysis. For these transcripts, protein FASTA sequences were downloaded. The ENSEMBL tran-
script IDs used are given in Suppl. Table 3 [download date April 2015]. Respective product sizes for each complete 
transcript were calculated using the Protein Molecular Weight Bioinformatic tool from the Sequence Manipulation 
Suite. Domain structures for alternative transcripts were determined using the InterPro protein sequence analysis 
and classification database. Signal peptide expression was determined using Phobius signal peptide predictor. 
Genecards, UNIPROT, Phosphosite plus, and TRANSDAB were used to identify predicted post-translational 
modifications of the SPARC family (primary variants). The Human Protein Atlas was accessed July 2016.
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